PDS Biotechnology (NASDAQ:PDSB – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.
Several other equities analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of PDS Biotechnology in a research report on Wednesday, April 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of PDS Biotechnology in a research report on Friday, July 17th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $9.00.
View Our Latest Stock Analysis on PDS Biotechnology
PDS Biotechnology Price Performance
PDS Biotechnology (NASDAQ:PDSB – Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. On average, research analysts forecast that PDS Biotechnology will post -0.52 EPS for the current fiscal year.
Hedge Funds Weigh In On PDS Biotechnology
Institutional investors and hedge funds have recently modified their holdings of the company. Armistice Capital LLC purchased a new stake in PDS Biotechnology during the fourth quarter valued at $2,182,000. Geode Capital Management LLC lifted its holdings in PDS Biotechnology by 8.0% in the fourth quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock valued at $401,000 after acquiring an additional 38,399 shares during the period. Squarepoint Ops LLC boosted its position in PDS Biotechnology by 116.1% in the third quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock worth $295,000 after purchasing an additional 156,662 shares during the last quarter. Commonwealth Equity Services LLC grew its stake in shares of PDS Biotechnology by 117.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock valued at $151,000 after purchasing an additional 106,300 shares during the period. Finally, Susquehanna International Group LLP grew its stake in shares of PDS Biotechnology by 603.7% during the 3rd quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock valued at $95,000 after purchasing an additional 80,937 shares during the period. 26.84% of the stock is currently owned by hedge funds and other institutional investors.
About PDS Biotechnology
PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.
Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.
Featured Stories
- Five stocks we like better than PDS Biotechnology
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
